Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Newcastle upon Tyne
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Newcastle upon Tyne, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2863 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 11 Oct 2026, 03:15 UTC
2863
Studies in scope
industry-sponsored, all four open statuses
1385
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 2015 Manchester 668 Birmingham 478 Glasgow 437 Cambridge 425
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca18 Hoffmann-La Roche14 Janssen Research & Development, LLC12 Novartis Pharmaceuticals11 Merck Sharp & Dohme LLC10
Site city
London2015 Manchester668 Birmingham478 Glasgow437 Cambridge425
All 429 cities
Target enrolment
to

Trials with a site in Newcastle upon Tyne

252 of 2863 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Not yet open
DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT07707895Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology, Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology
DrugsZL-1310·Obrixtamig·Atezolizumab
Boehringer Ingelheim
Phase 1/2
60
Leicester, Newcastle upon Tyne
2026-10-19
Recruiting
A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency.
NCT07559175Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF), Pancreatic Enzyme Abnormality, Pancreatic Diseases
DrugZenpep
Aimmune Nestlé Health Science US R&D, LLC
Phase 2
66
Liverpool, Belfast, Glasgow, Newcastle upon Tyne
2026-10
Recruiting
A Study in Adults With Geographic Atrophy
NCT07606365Geographic Atrophy
DrugSTL303
Sitala Bio LTD
Phase 2
300
London, Southampton, Leicester, Newcastle upon Tyne
2026-09-11
Recruiting
Incyte Corporation
Phase 3
426
Cambridge, Edinburgh, Harrow, Leeds, London, Newcastle upon Tyne, Oxford, Penzance
2026-09-08
Recruiting
AstraZeneca
Phase 3
1,072
Cambridge, Leeds, London, Newcastle upon Tyne, Sheffield
2026-08-31
Recruiting
Pivotal Study of N-acetyl-L-leucine for CACNA1A
NCT07221292CACNA1A, Spinocerebellar Ataxia Type 6, Episodic Ataxia Type 2, Familial Hemiplegic Migraine-1
DrugN-Acetyl-L-Leucine
IntraBio Inc
Phase 3
60
Newcastle upon Tyne, Oxford
2026-08-17
Not yet open
Entrada Therapeutics, Inc.
Phase 2
80
Leeds, Liverpool, London, Manchester, Newcastle upon Tyne, Oxford
2026-08
Recruiting
Prilenia
Phase 3
400
Aberdeen, Birmingham, Cardiff, Liverpool, Newcastle upon Tyne
2026-07-01
Recruiting
Hoffmann-La Roche
Phase 1
25
Liverpool, London, Newcastle upon Tyne
2026-06-29
Active, closed
Open-Label Extension Study of BBP-418 (Ribitol) for LGMD2I/R9
NCT07678775Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)
DrugRibitol
ML Bio Solutions, Inc.
Phase 3
107
London, Newcastle upon Tyne
2026-06-05
Recruiting
AstraZeneca
Phase 1/2
152
Belfast, Fulham, Guildford, London, Newcastle upon Tyne, Oxford
2026-06-03
Recruiting
Bayer
Phase 3
117
Leicester, Liverpool, Belfast, Glasgow, Newcastle upon Tyne, Leeds, Bristol
2026-06-01
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 3
250
Exeter, Newcastle upon Tyne, Windsor
2026-05-25
Recruiting
Kite, A Gilead Company
Phase 3
550
Cardiff, London, Newcastle upon Tyne
2026-05-22
Recruiting
Eli Lilly and Company
Phase 2
531
Cheadle, Hounslow, Macclesfield, Newcastle upon Tyne, Newquay, Rotherham, Surrey, Sutton in Ashfield
2026-05-06
Recruiting
Eli Lilly and Company
Phase 2
342
Cheadle, Hounslow, Macclesfield, Newcastle upon Tyne, Newquay, Rotherham, Surrey, Sutton in Ashfield
2026-04-29
Recruiting
Visugromab in Cachexia International Trial
NCT07112196Cancer-associated Cachexia
DrugsVisugromab·Visugromab RDE
CatalYm GmbH
Phase 2/3
518
Brighton, Cambridge, Dundee, Edinburgh, Guildford, Manchester, Newcastle upon Tyne
2026-04-16
Recruiting
SymBio Pharmaceuticals
Phase 3
180
Birmingham, Leeds, London, Manchester, Newcastle upon Tyne, Sheffield, Sutton
2026-03-17
Recruiting
Hoffmann-La Roche
Phase 3
2,000
Soham, Chippenham, Airdrie, Birmingham, Glasgow, Leicester, London, Newcastle upon Tyne
2026-03-16
Recruiting
Bristol-Myers Squibb
Phase 3
850
Manchester, Newcastle upon Tyne, Birmingham, Cambridge, Cardiff, Guildford, Leeds, Liverpool
2026-03-16
Recruiting
Novartis Pharmaceuticals
Phase 2
272
Bristol, London, Newcastle upon Tyne, Southampton
2026-03-09
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Bath, Cambridge, Greater London, Newcastle upon Tyne, Peterborough, Reading, Southampton, Stoke-on-Trent
2026-03-05
Recruiting
Norgine
Phase 3
212
Edinburgh, Newcastle upon Tyne, Sheffield, London, Birmingham
2025-12-29
Recruiting
Janssen Research & Development, LLC
Phase 3
800
Cardiff, Glasgow, London, Newcastle upon Tyne, Preston, Sutton
2025-12-19
Active, closed
Kailera
Phase 3
2,530
Soham, Torpoint, Hull, Stevenage, Leicester, Nottingham, Newcastle upon Tyne, Bradford
2025-12-18
Recruiting
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
NCT06793397Major Depressive Disorder (MDD), Depression in Adults, Depression - Major Depressive Disorder, Depression Disorders
DrugCYB003
Cybin IRL Limited
Phase 3
330
Cambridge, Doncaster, Edinburgh, Glasgow, London, Newcastle upon Tyne, Reading, Sheffield
2025-12-10
Recruiting
Boehringer Ingelheim
Phase 3
120
Birmingham, Bristol, Glasgow, Liverpool, London, Newcastle upon Tyne, Nottingham, Southampton
2025-12-09
Recruiting
Hoffmann-La Roche
Phase 2
160
Leicester, Doncaster, Newcastle upon Tyne, Barnet
2025-12-05
Recruiting
Sanofi
Phase 2
37
Newcastle upon Tyne, London
2025-12-02
Recruiting
AstraZeneca
Phase 1
40
Newcastle upon Tyne, Sutton
2025-11-25
Recruiting
TrueLok Elevate PMCF Study
NCT07079774Wound of Skin, Ulcers, Soft Tissue Defect
Orthofix s.r.l.
Observational
153
Hull, Newcastle upon Tyne
2025-11-24
Active, closed
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
NCT07161037Autosomal Dominant Polycystic Kidney Disease (ADPKD)
DrugVX-407
Vertex Pharmaceuticals Incorporated
Phase 2
26
Birmingham, London, Newcastle upon Tyne, Sheffield
2025-11-19
Recruiting
Bayer
Phase 3
111
Leicester, Liverpool, Belfast, Glasgow, Newcastle upon Tyne, Leeds, Bristol
2025-11-19
Recruiting
BioNTech SE
Phase 1/2
245
Leeds, London, Manchester, Newcastle upon Tyne, Sutton
2025-11-18
Recruiting
Prima Mente
Observational
1,000
London, Newport, Bradford, Bridgend, Llanelli, Newcastle upon Tyne, Penarth, Reading
2025-11-13
Recruiting
AstraZeneca
Phase 3
420
Glasgow, Scotland, London, Manchester, Newcastle upon Tyne, Nottingham
2025-11-11
Recruiting
AbbVie
Phase 3
561
Gloucester, London, Liverpool, Bristol, Newcastle upon Tyne, Sunderland
2025-11-05
Recruiting
Shionogi
Phase 2
45
Birmingham, London, Newcastle upon Tyne, Salford
2025-10-30
Recruiting
Novartis Pharmaceuticals
Phase 2
165
Brighton, Newcastle upon Tyne, Liverpool, London
2025-10-28
Recruiting
Pharvaris Netherlands B.V.
Phase 3
48
Bristol, Cambridge, Leicester, London, Newcastle upon Tyne, Plymouth
2025-10-16
Recruiting
Eli Lilly and Company
Phase 3
4,500
Aberdeen, Clifton, Enfield, Glasgow, Ipswich, Liverpool, London, Newcastle upon Tyne
2025-10-15
Active, closed
Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia
NCT07033481Nonfluent Variant Primary Progressive Aphasia (nfvPPA)
DrugNeflamapimod
EIP Pharma Inc
Phase 2
20
Cambridge, Newcastle upon Tyne
2025-10-02
Recruiting
AstraZeneca
Phase 1/2
91
London, Newcastle upon Tyne
2025-09-24
Recruiting
BioNTech SE
Phase 1/2
880
London, Newcastle upon Tyne, Sutton
2025-09-22
Recruiting
Sanofi
Phase 4
218
Dundee, Newcastle upon Tyne, Southampton, Leicester, Bradford, Sheffield
2025-09-22
Recruiting
LEO Pharma
Phase 2
135
Bristol, London, Newcastle upon Tyne, Salford, Stourbridge
2025-09-11
Recruiting
Bristol-Myers Squibb
Phase 2
182
Birmingham, London, Newcastle upon Tyne
2025-09-09
Recruiting
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT07011719Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
DrugsCasdatifan·Cabozantinib
Arcus Biosciences, Inc.
Phase 3
720
Cambridge, Cottingham, Exeter, Glasgow, Leeds, London, Manchester, Newcastle upon Tyne
2025-09-08
Recruiting
Sanofi
Phase 2
30
Milton Keynes, Newcastle upon Tyne
2025-09-02
Recruiting
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
NCT06989359IgAN, C3G, Complement-mediated Kidney Disease, IgA Nephropathy (IgAN)
ADARx Pharmaceuticals, Inc.
Phase 2
45
Leicester, Newcastle upon Tyne
2025-08-28
Recruiting
Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
NCT07151040Solid Tumor, Colorectal Cancer (CRC), Squamous Cell Carcinoma of Head and Neck, Non-Small Cell Lung Cancer (NSCLC)
One-carbon Therapeutics AB
Phase 1/2
43
Newcastle upon Tyne
2025-08-22
Active, closed
An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM)
NCT06961344Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)
Tisento Therapeutics
Phase 2
44
London, Newcastle upon Tyne
2025-08-18
Recruiting
BioNTech SE
Phase 1/2
1,438
Birmingham, Cardiff, Glasgow, Liverpool, London, Manchester, Newcastle upon Tyne, Southampton
2025-08-12
Recruiting
Novartis Pharmaceuticals
Phase 2
407
Edinburgh, Oxford, Aberdeen, London, Newcastle upon Tyne, Salford, Southampton
2025-08-07
Recruiting
GB-PRIME: An Early Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices
NCT07127172Tetraplegia/Tetraparesis, Quadriplegia, Quadriplegia/Tetraplegia, Cervical Spinal Cord Injury
Neuralink Corp
Not applicable
7
London, Newcastle upon Tyne
2025-07-31
Recruiting
Sanofi
Phase 1/2
32
Newcastle upon Tyne
2025-07-23
Recruiting
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
NCT06570798Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis
DrugsUplizna·Inebilizumab·Blinatumomab
Amgen
Phase 2
220
Cambridge, Edinburgh, Leicester, Newcastle upon Tyne
2025-07-16
Recruiting
Entrada Therapeutics, Inc.
Phase 1/2
24
Leeds, Liverpool, London, Manchester, Newcastle upon Tyne, Oxford
2025-06-30
Recruiting
AstraZeneca
Phase 2
987
Bradford, Cottingham, Glasgow, Harrow, London, Newcastle upon Tyne, Thetford, Wythenshawe
2025-06-27
Active, closed
Calluna Pharma AS
Phase 2
150
Birmingham, Edinburgh, Leeds, London, Manchester, Newcastle upon Tyne, Oxford, Southampton
2025-06-20
Recruiting
BeOne Medicines
Phase 3
630
Bournemouth, Headington, Leeds, London, Metropolitan Borough of Wirral, Newcastle upon Tyne, Truro
2025-06-11
Recruiting
A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD
NCT07038200Facioscapulohumeral Muscular Dystrophy, FSHD, FSHD - Facioscapulohumeral Muscular Dystrophy, FSHD1
DrugDel-brax
Avidity Biosciences, Inc.
Phase 3
200
London, Newcastle upon Tyne, Sheffield
2025-06-10
Recruiting
Boehringer Ingelheim
Phase 2
300
Camberley, Gloucester, Harrow, Liverpool, London, Newcastle upon Tyne, Sunderland, Westcliff-on-Sea
2025-06-05
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
50
Birmingham, Newcastle upon Tyne, Cardiff, Sutton
2025-05-26
Recruiting
Surgical vs Transcatheter Aortic Valve Replacement in YOUNG Patients
NCT06861361Symptomatic Severe Aortic Stenosis
Ceric Sàrl
Not applicable
1,180
Belfast, Brighton, Cambridge, Cottingham, Coventry, London, Newcastle upon Tyne, Sheffield
2025-05-15
By invitation
Sanofi
Phase 2
71
Gloucester, Manchester, Newcastle upon Tyne
2025-05-12
Active, closed
FARAPULSE Workflow Assessment Registry
NCT06656884Atrial Fibrillation (AF)
Boston Scientific Corporation
Observational
524
Bournemouth, Cambridge, Leicester, Newcastle upon Tyne, Southampton
2025-05-06
Recruiting
ModernaTX, Inc.
Phase 2
180
Bristol, Cardiff, Edinburgh, Glasgow, London, Newcastle upon Tyne, Sheffield
2025-04-16
Recruiting
AbbVie
Observational
700
Milton Keynes, Truro, Cheltenham, Portsmouth, Airdrie, Nottingham, Manchester, Newcastle upon Tyne
2025-03-28
Recruiting
Hoffmann-La Roche
Phase 3
600
Cambridge, Harrow, Liverpool, London, Newcastle upon Tyne, North Shields, Nottingham
2025-03-17
Active, closed
Hoffmann-La Roche
Phase 4
274
Cardiff, Leeds, Liverpool, London, Newcastle upon Tyne, Wolverhampton
2025-03-14
Recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
440
Cambridge, London, Oxford, Manchester, Newcastle upon Tyne, Sheffield
2025-03-12
By invitation
Longboard Pharmaceuticals
Phase 3
324
Cardiff, Newcastle upon Tyne, Glasgow, London
2025-02-12
Active, closed
Sanofi
Phase 3
231
London, Oxford, Bradford, Newcastle upon Tyne
2025-02-12
Active, closed
GlaxoSmithKline
Phase 2
307
Bradford, London, Newcastle upon Tyne
2025-02-10
Recruiting
Bristol-Myers Squibb
Phase 1/2
416
London, Glasgow, Birmingham, Newcastle upon Tyne
2025-02-04
Recruiting
Physio-Assist
Not applicable
622
Belfast, Birmingham, Edinburgh, Manchester, Newcastle upon Tyne
2025-02-03
Recruiting
BioNTech SE
Phase 3
621
Manchester, Chelsea, Sutton, Huddersfield, Newcastle upon Tyne, Nottingham, Oxford, Dundee
2025-02-03
Recruiting
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
NCT06680830Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD)
Neuron23 Inc.
Phase 2
150
London, Newcastle upon Tyne, Dundee, Harrow
2025-01-17
Recruiting
Italfarmaco
Phase 2
18
Leeds, London, Newcastle upon Tyne, Oxford
2025-01-02
Active, closed
Vertex Pharmaceuticals Incorporated
Observational
401
Birmingham, London, Newcastle upon Tyne, Sheffield
2024-12-19
Active, closed
GlaxoSmithKline
Phase 1
86
Cambridge, Exeter, London, Newcastle upon Tyne
2024-12-11
Recruiting
PepGen Inc
Phase 2
24
Salford, London, Cardiff, Newcastle upon Tyne
2024-12-10
Recruiting
Corbus Pharmaceuticals Inc.
Phase 1/2
156
Newcastle upon Tyne, Manchester, Birkenhead, Edinburgh, Glasgow, London
2024-12-04
Active, closed
H. Lundbeck A/S
Phase 3
401
Salford, Oxford, Glasgow, Newcastle upon Tyne, Exeter, London
2024-12-03
Recruiting
AstraZeneca
Phase 3
1,160
Aberdeen, Cambridge, Edinburgh, Exeter, Greater London, London, Manchester, Newcastle upon Tyne
2024-11-27
Recruiting
UCB Biopharma SRL
Phase 3
450
Bath, Belfast, Leeds, London, Newcastle upon Tyne, Sheffield, West Bromwich
2024-11-21
Recruiting
AstraZeneca
Phase 3
1,160
Aberdeen, Cambridge, Edinburgh, Exeter, Greater London, London, Manchester, Newcastle upon Tyne
2024-11-18
Active, closed
Longboard Pharmaceuticals
Phase 3
367
Cardiff, Newcastle upon Tyne, Southampton, Glasgow, Birmingham, London
2024-11-11
Recruiting
Regeneron Pharmaceuticals
Phase 3
975
Liverpool, York, Bristol, London, Newcastle upon Tyne
2024-10-30
Recruiting
GlaxoSmithKline
Phase 1
845
Edinburgh, Glasgow, London, Manchester, Newcastle upon Tyne
2024-09-30
Active, closed
Longboard Pharmaceuticals
Phase 3
96
Newcastle upon Tyne, Glasgow, London
2024-09-25
Active, closed
Merus B.V.
Phase 3
699
Cambridge, Cardiff, London, Manchester, Newcastle upon Tyne, Northwood, Southampton, Sutton
2024-09-25
Active, closed
Cerevance
Phase 3
330
Newcastle upon Tyne, Bury, London, Plymouth
2024-09-20
Recruiting
Janssen Research & Development, LLC
Phase 2/3
274
Bristol, Headington, London, Newcastle upon Tyne
2024-09-19
Recruiting
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
NCT06528314NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
DrugEfruxifermin
Akero Therapeutics, Inc
Phase 3
2,150
London, Nottingham, Birmingham, Newcastle upon Tyne, Whitechapel
2024-09-04
Recruiting
Janssen Research & Development, LLC
Phase 2
210
Belfast, Colchester, Eastbourne, Liverpool, London, Manchester, Newcastle upon Tyne
2024-08-26
Active, closed
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
NCT06533059Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer
Alterome Therapeutics, Inc.
Phase 1
110
London, Manchester, Newcastle upon Tyne, Sutton
2024-08-22
Recruiting
AbbVie
Phase 3
675
Plymouth, London, Southampton, Glasgow, Manchester, Newcastle upon Tyne
2024-08-19
Recruiting
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
NCT06395103B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma
DrugZilovertamab vedotin
Merck Sharp & Dohme LLC
Phase 1/2
90
Birmingham, Newcastle upon Tyne, London, Sutton, Cardiff
2024-08-16
Active, closed
Genmab
Phase 3
379
Truro, Airdrie, Nottingham, Newcastle upon Tyne
2024-08-13
Recruiting
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
NCT06545942Advanced Solid Tumor, Metastatic Solid Tumor, Prostate Cancer, Pancreas Cancer
DrugOlaparib
MOMA Therapeutics
Phase 1
220
London, Manchester, Newcastle upon Tyne
2024-08-13
Recruiting
AstraZeneca
Phase 3
1,018
London, Newcastle upon Tyne, Norwich, Nottingham, Plymouth, Southampton
2024-08-07
Active, closed
BioNTech SE
Phase 2
110
Birmingham, Cardiff, Dundee, Exeter, Huddersfield, Leeds, London, Newcastle upon Tyne
2024-08-05
By invitation
Biohaven Therapeutics Ltd.
Phase 2
660
Swansea, Glasgow, Salford, Liverpool, Oxford, Cardiff, London, Newcastle upon Tyne
2024-07-30
Recruiting
LDR Médical SAS
Observational
100
London, Newcastle upon Tyne, Southampton
2024-07-18
Active, closed
Merck Sharp & Dohme LLC
Phase 3
300
Bodelwyddan, Gloucester, Lincoln, Boston, London, Newcastle upon Tyne, Newport
2024-07-16
Active, closed
AstraZeneca
Phase 3
339
Cambridge, Leeds, London, Newcastle upon Tyne
2024-06-29
Recruiting
Boehringer Ingelheim
Phase 1/2
768
Cardiff, Leeds, London, Manchester, Newcastle upon Tyne, Nottingham, Sutton
2024-06-28
Active, closed
AbbVie
Phase 3
1,400
Truro, Dunfermline, Gloucester, London, Harrogate, Shoreham-by-Sea, Bristol, Newcastle upon Tyne
2024-06-27
Active, closed
Merus B.V.
Phase 3
621
Cambridge, Cardiff, Glasgow, Liverpool, London, Manchester, Middlesex, Newcastle upon Tyne
2024-06-25
Recruiting
Eli Lilly and Company
Phase 3
300
Cambridge, Glagow, Leeds, Leicester, Liverpool, London, Newcastle upon Tyne, Sheffield
2024-06-03
Active, closed
Boehringer Ingelheim
Phase 2
190
Colchester, Liverpool, London, Newcastle upon Tyne
2024-05-15
Active, closed
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
NCT06295731Head and Neck Squamous Cell Carcinoma (HNSCC)
DrugsKeytruda·Pembrolizumab
Inhibrx Biosciences, Inc
Phase 2/3
410
Chelsea, Northwood, Newcastle upon Tyne, Sutton, Aberdeen, Cambridge, Manchester, Norwich
2024-05-14
Active, closed
Biohaven Therapeutics Ltd.
Phase 2/3
390
Swansea, Glasgow, Salford, Oxford, Cardiff, London, Newcastle upon Tyne
2024-05-13
Recruiting
Eli Lilly and Company
Phase 3
510
Bristol, Chelsea, Great Yarmouth, London, Newcastle upon Tyne, Stockport
2024-04-29
Recruiting
Janssen Research & Development, LLC
Phase 3
641
Bristol, London, Newcastle upon Tyne, Sheffield, Southampton, Sutton
2024-04-18
Active, closed
An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency
NCT06255782Ornithine Transcarbamylase Deficiency, Ornithine Transcarbamylase Deficiency Disease, Ornithine Carbamoyltransferase Deficiency (Disorder), Urea Cycle Disorders, Inborn
iECURE, Inc.
Phase 3
20
London, Newcastle upon Tyne
2024-04-08
Recruiting
Merck Sharp & Dohme LLC
Phase 3
780
Cambridge, Northwood, London, Oxford, Newcastle upon Tyne
2024-04-03
By invitation
ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation
NCT05932615Aortic Valve Stenosis, Heart Valve Diseases, Aortic Valve Disease, Heart Disease Structural Disorder
Abbott Medical Devices
Not applicable
1,500
Brighton, London, Newcastle upon Tyne
2024-03-15
Recruiting
First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT06217822Advanced Metastatic Castration-resistant Prostate Cancer, Prostate Specific Membrane Antigen (PSMA) Expression
Bayer
Phase 1
198
London, Sutton, Newcastle upon Tyne
2024-03-07
Active, closed
Eli Lilly and Company
Phase 3
17,300
Blackpool, Bristol, Cheadle, Enfield, Glasgow, Hull, London, Newcastle upon Tyne
2024-03-05
Recruiting
Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN
NCT06209736C3 Glomerulopathy, Idiopathic Immune Complex-Mediated Glomerulonephritis
DrugOMS906 study drug
Omeros Corporation
Phase 2
20
Leicester, Newcastle upon Tyne
2024-03-01
Recruiting
Novartis Pharmaceuticals
Phase 3
50
Glasgow, Newcastle upon Tyne, London
2024-02-28
Recruiting
Italfarmaco
Phase 3
138
Newcastle upon Tyne, Oxford, Glasgow
2024-02-19
Active, closed
Genmab
Phase 3
1,095
Plymouth, London, Portsmouth, Leeds, Manchester, Newcastle upon Tyne
2024-02-05
Active, closed
Astellas Gene Therapies
Not applicable
119
Cambridge, Newcastle upon Tyne, Salford
2024-02-01
Active, closed
Sanofi
Phase 3
260
Cardiff, London, Leeds, Manchester, Newcastle upon Tyne
2024-01-23
Recruiting
Astellas Pharma Global Development, Inc.
Phase 3
100
Cardiff, Glasgow, Liverpool, London, Newcastle upon Tyne, Nottingham, Southampton
2024-01-16
Active, closed
Sarepta Therapeutics, Inc.
Phase 3
17
Newcastle upon Tyne
2024-01-15
Active, closed
Sanofi
Phase 3
943
Gwent, Cardiff, Exeter, London, Newcastle upon Tyne, Inverness, Canterbury, Salford
2023-12-27
Recruiting
Biogen
Observational
20
London, Salford, Southampton, Nottingham, Oswestry, Sheffield, Newcastle upon Tyne, Birmingham
2023-12-15
Recruiting
Akero Therapeutics, Inc
Phase 3
1,650
Birmingham, Cambridge, Liverpool, London, Newcastle upon Tyne
2023-12-01
Active, closed
AstraZeneca
Phase 3
1,898
Aberdeen, Birmingham, Cambridge, Glasgow, Guildford, London, Manchester, Newcastle upon Tyne
2023-11-21
Recruiting
Autolus Limited
Phase 1
30
London, Manchester, Newcastle upon Tyne
2023-11-16
Active, closed
Akero Therapeutics, Inc
Phase 3
700
Liverpool, London, Newcastle upon Tyne
2023-11-10
Active, closed
AstraZeneca
Phase 3
863
Cambridge, Leeds, Leicester, London, Manchester, Newcastle upon Tyne, Portsmouth, Taunton
2023-11-09
Active, closed
Novartis Pharmaceuticals
Phase 3
612
Doncaster, Leeds, Liverpool, Newcastle upon Tyne, Swindon
2023-10-27
Recruiting
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT05882058Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma
DrugObrixtamig
Boehringer Ingelheim
Phase 2
204
Leicester, London, Manchester, Newcastle upon Tyne
2023-10-13
Active, closed
Merck Sharp & Dohme LLC
Phase 3
14,550
Bristol, Exeter, Walsall, London, Newcastle upon Tyne, Clydebank, Romford, Corby
2023-10-09
By invitation
Sarepta Therapeutics, Inc.
Phase 3
400
London, Oxford, Newcastle upon Tyne
2023-09-27
Recruiting
Gilead Sciences
Phase 3
402
Hull, Ipswich, Leeds, London, Newcastle upon Tyne, Oxford, Sheffield, Wolverhampton
2023-09-07
Recruiting
Incyte Corporation
Phase 1
570
Cambridge, London, Manchester, Newcastle upon Tyne
2023-07-24
Recruiting
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
NCT05985655Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC)
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Phase 1/2
230
Glasgow, London, Manchester, Newcastle upon Tyne, Oxford
2023-07-06
Active, closed
Sarepta Therapeutics, Inc.
Phase 3
148
London, Oxford, Newcastle upon Tyne
2023-05-31
Active, closed
ML Bio Solutions, Inc.
Phase 3
112
London, Newcastle upon Tyne
2023-05-31
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
342
London, Newcastle upon Tyne
2023-05-31
Active, closed
Vertex Pharmaceuticals Incorporated
Phase 1/2
7
Newcastle upon Tyne, Oxford
2023-05-16
Active, closed
Servier Affaires Médicales
Phase 3
299
Birmingham, Glasgow, London, Manchester, Newcastle upon Tyne
2023-05-03
Active, closed
OncoSil Medical Limited
Phase 2
88
London, Manchester, Newcastle upon Tyne, Southampton
2023-04-26
Active, closed
Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System in Complex PCI Patients
NCT05705973Cardiovascular Disease, Coronary Artery Occlusion, Ischemic Heart Disease
Terumo Europe N.V.
Observational
3,000
Brighton, Lincoln, London, Londonderry, Newcastle, Newcastle upon Tyne, Plymouth, Worcester
2023-04-25
Active, closed
Bial R&D Investments, S.A.
Phase 2
237
Dundee, Glasgow, London, Newcastle upon Tyne, Plymouth
2023-03-31
Recruiting
Iovance Biotherapeutics, Inc.
Phase 3
670
Birmingham, Newcastle upon Tyne, Chelsea, Glasgow, London
2023-03-30
Active, closed
Bristol-Myers Squibb
Phase 3
579
London, Headington, Oxford, Newcastle upon Tyne
2023-03-06
Active, closed
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
NCT05566795Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma
DrugsTovorafenib·Carboplatin
Day One Biopharmaceuticals, Inc.
Phase 3
418
Birmingham, Leeds, Liverpool, Manchester, Newcastle upon Tyne, Oxford, Southampton, Belfast
2023-02-27
Active, closed
Merck Sharp & Dohme LLC
Phase 3
553
East Sussex, Crumpsall, London, Newcastle upon Tyne, Birmingham
2023-02-20
Active, closed
Hoffmann-La Roche
Phase 2
51
London, Newcastle upon Tyne
2023-02-07
Recruiting
Jazz Pharmaceuticals
Phase 3
510
Cambridge, Glasgow, Liverpool, Manchester, Sutton, Newcastle upon Tyne, Leeds, London
2023-01-23
Active, closed
Calcilytix Therapeutics, Inc., a BridgeBio company
Phase 3
67
Newcastle upon Tyne, Norwich
2023-01-06
Recruiting
DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis
NCT05701917Venous Thromboembolism, Deep Venous Thrombosis, Post-Thrombotic Syndrome
Inari Medical
Not applicable
300
London, Newcastle upon Tyne, Oxford
2023-01-06
Active, closed
Phase 2b Study of GSK4532990 in Adults With NASH
NCT05583344Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
DrugGSK4532990
GlaxoSmithKline
Phase 2
284
Nottingham, Cannock, London, Manchester, Newcastle upon Tyne
2023-01-02
Active, closed
Novartis Pharmaceuticals
Phase 3
20
London, Newcastle upon Tyne
2022-12-19
Active, closed
Janssen Research & Development, LLC
Phase 1/2
57
London, Newcastle upon Tyne, Sutton
2022-12-13
Recruiting
Pfizer
Phase 3
100
Newcastle upon Tyne, Birmingham, London, Manchester
2022-12-09
Active, closed
AstraZeneca
Phase 3
1,174
Cambridge, Cardiff, Edinburgh, Greater London, London, Londonderry, Manchester, Newcastle upon Tyne
2022-11-28
Active, closed
Bayer
Phase 1
284
London, Oxford, Sutton, Newcastle upon Tyne
2022-11-04
Recruiting
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
400
Newcastle upon Tyne, Glasgow, Sutton, Bristol, Cambridge, Leeds, London, Manchester
2022-10-24
Active, closed
Janssen Research & Development, LLC
Phase 3
864
Blackpool, Dundee, London, Newcastle upon Tyne, Nottingham, Plymouth, Sutton, Wolverhampton
2022-10-13
Active, closed
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
NCT05347095Fistulizing Crohns Disease, Perianal Crohns Disease
DrugGuselkumab
Janssen-Cilag Ltd.
Phase 3
288
Hull, London, Newcastle upon Tyne, Salford
2022-09-27
Recruiting
Celgene
Phase 3
810
Cambridge, Truro, Airdrie, London, Leicester, Barnet, Newcastle upon Tyne, Stoke-on-Trent
2022-09-20
Active, closed
Dyne Therapeutics
Phase 1/2
127
London, Newcastle upon Tyne, Salford
2022-09-05
Active, closed
Atamyo Therapeutics
Phase 1
6
Newcastle upon Tyne
2022-09-01
Active, closed
Dyne Therapeutics
Phase 1/2
86
Liverpool, Newcastle upon Tyne, Leeds, Bristol, London
2022-08-12
Active, closed
Janssen Research & Development, LLC
Phase 3
418
Birmingham, London, Newcastle upon Tyne, Sutton
2022-08-05
Active, closed
Novartis Pharmaceuticals
Phase 3
506
Doncaster, Leeds, Liverpool, Newcastle upon Tyne, Swindon
2022-08-04
Active, closed
Novartis Pharmaceuticals
Phase 3
610
Newcastle upon Tyne, Edinburgh
2022-07-08
Active, closed
Incyte Corporation
Phase 1
291
London, Newcastle upon Tyne
2022-07-05
Recruiting
AstraZeneca
Phase 1/2
695
Glasgow, Scotland, London, Newcastle upon Tyne
2022-06-24
Recruiting
BioNTech SE
Phase 1
320
Cambridge, Cardiff, Liverpool, London, Newcastle upon Tyne
2022-06-17
Recruiting
Priothera SAS
Phase 3
366
Birmingham, Cardiff, Glasgow, London, Manchester, Newcastle upon Tyne, Nottingham, Oxford
2022-06-16
Active, closed
PASS of Paediatric Patients Initiating Selumetinib
NCT05388370Neurofibromatosis Type 1
AstraZeneca
Observational
124
London, Manchester, Newcastle upon Tyne
2022-05-23
Active, closed
Pierre Fabre Medicament
Phase 3
815
Preston, Newcastle upon Tyne
2022-05-02
Active, closed
Sanofi
Phase 4
1,339
Cambridge, Oxford, Bradford, Liverpool, Newcastle upon Tyne, Wakefield
2021-12-16
Recruiting
Johnson & Johnson Enterprise Innovation Inc.
Phase 3
500
Edinburgh, Glasgow, Guildford, London, Newcastle upon Tyne, Nottingham
2021-12-10
Recruiting
Pfizer
Phase 3
245
Newcastle upon Tyne, London
2021-11-17
Recruiting
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
NCT05065216Acute Stroke, Ischemic Stroke, Stroke
DiaMedica Therapeutics Inc
Phase 2/3
728
Exeter, Newcastle upon Tyne, Cambridge, London, Stoke-on-Trent, Kirkcaldy, Leeds, Middlesbrough
2021-11-07
Active, closed
Pfizer
Phase 3
77
London, Newcastle upon Tyne, Truro
2021-09-29
Active, closed
Mirum Pharmaceuticals, Inc.
Phase 2
333
Southampton, Birmingham, Belfast, London, Newcastle upon Tyne, Nottingham
2021-09-22
Recruiting
Novartis Pharmaceuticals
Phase 3
540
Newcastle upon Tyne, Cambridge, Leicester, London, Salford
2021-09-20
Active, closed
Hoffmann-La Roche
Phase 1/2
42
London, Manchester, Newcastle upon Tyne
2021-09-14
Recruiting
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
NCT05006716B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
DrugTacabrutideg
BeOne Medicines
Phase 1/2
689
Edinburgh, Leeds, Newcastle upon Tyne, Newmarket, Norwich, Nottingham, Plymouth
2021-09-13
Active, closed
Inventiva Pharma
Phase 3
1,000
London, Manchester, Newcastle upon Tyne, Nottingham, Preston, Sheffield, Surrey Quays, Glasgow
2021-08-19
Recruiting
Novartis Pharmaceuticals
Phase 3
98
Glasgow, Newcastle upon Tyne, London
2021-07-28
Active, closed
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
NCT04969835Salivary Gland Tumor, Urothelial Carcinoma, Ovarian Carcinoma, Breast Cancer
Avacta Life Sciences Ltd
Phase 1
158
Glasgow, Leeds, London, Manchester, Newcastle upon Tyne, Sheffield
2021-07-16
Active, closed
Hoffmann-La Roche
Phase 3
451
Bristol, Liverpool, London, Newcastle upon Tyne, Sunderland, Wolverhampton
2021-07-14
Active, closed
Merck Sharp & Dohme LLC
Phase 3
815
Cambridge, Glasgow, London, Newcastle upon Tyne, Sheffield
2021-05-12
Active, closed
Hoffmann-La Roche
Phase 3
557
Birmingham, Liverpool, London, Manchester, Newcastle upon Tyne, Oxford
2021-04-26
Active, closed
Sarepta Therapeutics, Inc.
Observational
205
London, Newcastle upon Tyne
2021-04-22
Recruiting
Day One Biopharmaceuticals, Inc.
Phase 2
141
London, Newcastle upon Tyne
2021-04-22
Recruiting
A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes
NCT04786262Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, Severe Hypoglycemia
DrugZimislecel
Vertex Pharmaceuticals Incorporated
Phase 3
57
Headington, Edinburgh, London, Newcastle upon Tyne
2021-03-29
Active, closed
Karyopharm Therapeutics Inc
Phase 3
353
London, Oxford, Boston, Liverpool, Newcastle upon Tyne
2021-03-11
Active, closed
Galderma R&D
Phase 3
500
Dudley, Glasgow, London, Newcastle upon Tyne
2021-01-11
Active, closed
Pfizer
Phase 3
841
Newcastle upon Tyne, Sutton, Birmingham, London, Oxford
2020-12-21
Active, closed
Mirum Pharmaceuticals, Inc.
Phase 2
182
London, Oxford, Belfast, Birmingham, Cambridge, Edinburgh, Leeds, Newcastle upon Tyne
2020-12-18
Active, closed
Hoffmann-La Roche
Phase 3
769
London, Newcastle upon Tyne, Plymouth
2020-12-03
Active, closed
Janssen Research & Development, LLC
Phase 1
136
Newcastle upon Tyne
2020-11-13
Active, closed
Pfizer
Phase 3
114
Newcastle upon Tyne, Liverpool, London
2020-11-05
Active, closed
Genmab
Phase 1/2
543
Manchester, Newcastle upon Tyne, Plymouth
2020-11-03
Recruiting
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT04585750Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor
DrugsRezatapopt·Keytruda·Pembrolizumab
PMV Pharmaceuticals, Inc
Phase 1/2
300
London, Newcastle upon Tyne
2020-10-29
Active, closed
Astellas Gene Therapies
Phase 1/2
11
Newcastle upon Tyne
2020-10-27
Active, closed
AstraZeneca
Phase 3
370
London, Manchester, Newcastle upon Tyne, Sutton
2020-10-02
Active, closed
Ipsen
Phase 3
161
Newcastle upon Tyne, Belfast, Camberley, Cambridge, Hull, London, Nottingham, Plymouth
2020-09-24
Active, closed
AbbVie
Phase 3
330
London, Lincoln, Great Yarmouth, Birmingham, Edinburgh, Newcastle upon Tyne
2020-08-31
Active, closed
Hoffmann-La Roche
Phase 1/2
237
London, Manchester, Newcastle upon Tyne, Nottingham
2020-08-12
Active, closed
GlaxoSmithKline
Phase 3
242
Basingstoke, Glasgow, London, Newcastle upon Tyne, Nottingham, Plymouth, Reading Berkshire, Southampton
2020-07-14
Active, closed
Actelion
Phase 3
935
London, Newcastle upon Tyne, Sheffield
2020-06-30
Active, closed
Janssen Research & Development, LLC
Phase 3
419
Birmingham, Bristol, Cardiff, London, Manchester, Newcastle upon Tyne
2020-06-12
Active, closed
Autolus Limited
Phase 1/2
153
Cambridge, London, Manchester, Glasgow, Newcastle upon Tyne, Birmingham, Bristol
2020-06-03
Active, closed
Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi
NCT04042025Spinal Muscular Atrophy Type I, Spinal Muscular Atrophy Type II, Spinal Muscular Atrophy Type III, SMA
DrugsOnasemnogene Abeparvovec-xioi·Zolgensma
Novartis Gene Therapies
Phase 3
85
London, Newcastle upon Tyne
2020-02-10
Active, closed
EMD Serono Research & Development Institute, Inc.
Phase 1
161
Cambridge, Manchester, Newcastle upon Tyne, Sutton
2019-12-20
Active, closed
Cold Agglutinin Disease Real World Evidence Registry
NCT05791708Cold Agglutinin Disease (CAD), Cold Agglutinin Syndrome (CAS)
RECORDATI GROUP
Observational
429
Truro, Carlisle, Gillingham, London, Salford, Airdrie, Newcastle upon Tyne, Middlesbrough
2019-12-12
Active, closed
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
NCT04180371Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer
DrugsNuzefatide pevedotin·Opdivo·Nivolumab
BicycleTx Limited
Phase 1/2
288
London, Manchester, Cambridge, Leeds, Newcastle upon Tyne
2019-11-07
Active, closed
Eli Lilly and Company
Phase 3
30
Bristol, Cambridge, Liverpool, Newcastle upon Tyne, Southampton, London, Sheffield
2019-10-16
Recruiting
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
NCT03955445C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
225
Newcastle upon Tyne, Cardiff, London
2019-10-03
Active, closed
RECORDATI GROUP
Observational
125
Newcastle upon Tyne, Birmingham, Southampton
2019-09-30
By invitation
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
NCT03683186PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension
United Therapeutics
Phase 3
1,000
London, Newcastle upon Tyne, Glasgow
2019-09-23
Active, closed
Pfizer
Phase 3
51
Newcastle upon Tyne, Glasgow, London
2019-07-29
Active, closed
Madrigal Pharmaceuticals, Inc.
Phase 3
1,759
Birmingham, Cambridge, Chorley, Hardwick, Liverpool, London, Manchester, Newcastle upon Tyne
2019-03-28
Active, closed
The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension
NCT03614260Hypertension, Vascular Diseases, Cardiovascular Diseases
ReCor Medical, Inc.
Not applicable
224
Basildon, Bournemouth, Canterbury, Cardiff, London, Newcastle upon Tyne
2018-12-14
Active, closed
Merck Sharp & Dohme LLC
Phase 2
329
Oxford, Manchester, Newcastle upon Tyne, Sheffield
2018-12-12
Recruiting
Hoffmann-La Roche
Phase 3
1,000
Bristol, Liverpool, London, Newcastle upon Tyne, Sunderland, Wolverhampton
2018-09-20
Active, closed
AbbVie
Phase 3
1,242
Cambridge, Exeter, Edinburgh, London, Southampton, Barnsley, Liverpool, Newcastle upon Tyne
2018-08-28
By invitation
Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells
NCT03628612Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy, Multiple Myeloma, DLBCL, ALL, Adult and Pediatric
Autolus Limited
Phase 2
500
Glasgow, London, Manchester, Newcastle upon Tyne
2018-08-02
Active, closed
Hoffmann-La Roche
Phase 1/2
211
Leicester, London, Newcastle upon Tyne
2018-05-08
Active, closed
Merck Sharp & Dohme LLC
Phase 3
797
Leicester, Metropolitan Borough of Wirral, London, Sutton, Nottingham, Birmingham, Newcastle upon Tyne, Plymouth
2018-04-24
Active, closed
Pyruvate Kinase Deficiency Global Longitudinal Registry
NCT03481738Pyruvate Kinase Deficiency
Agios Pharmaceuticals, Inc.
Observational
500
London, Newcastle upon Tyne
2018-04-23
Recruiting
Octapharma
Observational
200
Headington, Birmingham, London, Newcastle upon Tyne
2018-02-13
Recruiting
LivaNova
Observational
500
Leicester, London, Newcastle upon Tyne, Wells
2017-12-14
Active, closed
Gilead Sciences
Phase 3
340
Birmingham, Hull, London, Newcastle upon Tyne, Nottingham, Plymouth, Portsmouth
2017-12-12
Recruiting
Italfarmaco
Phase 2/3
206
Liverpool, Gobowen, London, Newcastle upon Tyne
2017-10-24
Active, closed
Global Fenestrated Anaconda Clinical STudy
NCT03180996Abdominal Aortic Aneurysm
Vascutek Ltd.
Observational
160
Newcastle upon Tyne, Camberley, London
2017-09-11
Active, closed
BioVentrix Revivent TC™ System Clinical Study
NCT02931240Ventricular Dysfunction, Left
BioVentrix
Not applicable
126
Cambridge, Newcastle upon Tyne
2017-08-29
Active, closed
Janssen Research & Development, LLC
Phase 1/2
234
Glasgow, London, Manchester, Newcastle upon Tyne
2016-11-21
Active, closed
Janssen Research & Development, LLC
Phase 1
751
Manchester, Newcastle upon Tyne, Sutton
2016-05-24
Active, closed
Hoffmann-La Roche
Phase 1/2
69
London, Newcastle upon Tyne
2016-05-03
Active, closed
AstraZeneca
Phase 1/2
264
Cambridge, Dundee, Glasgow, Greater London, London, Manchester, Newcastle upon Tyne, Sutton
2016-03-17
Active, closed
Tesaro, Inc.
Phase 1
729
Newcastle upon Tyne, Aberdeen, London, Manchester, Oxford, Sutton
2016-03-07
Recruiting
Boston Scientific Corporation
Observational
300
Bristol, Glasgow, London, Newcastle upon Tyne
2016-03-07
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,052
Carlisle, Dundee, Glasgow, London, Newcastle upon Tyne, Oxford, Plymouth, Scunthorpe
2015-11-27
By invitation
Registry of Patients With Hypophosphatasia
NCT02306720Hypophosphatasia (HPP)
Alexion Pharmaceuticals, Inc.
Observational
1,571
Bristol, London, Leicester, Stanmore, Oxford, Sheffield, Newcastle upon Tyne, Birmingham
2015-01-20
Active, closed
AstraZeneca
Phase 1
197
Edinburgh, London, Manchester, Newcastle upon Tyne, Northwood, Oxford, Sutton
2008-10-27
Recruiting
Pompe Disease Registry Protocol
NCT00231400Glycogen Storage Disease Type II, Pompe Disease
Genzyme, a Sanofi Company
Observational
2,000
Cambridge, Cardiff, Birmingham, London, Glasgow, Salford, Manchester, Newcastle upon Tyne
2004-09-15
Rows per page Showing 1–252 of 252
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 October 2026. https://priyalifescience.com/clinical-trials-uk/city/newcastle-upon-tyne

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,863 studies in total at the last sync on 11 Oct 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 252 of those studies with a site in Newcastle upon Tyne.

How many clinical trials are recruiting in Newcastle upon Tyne?

124 of the 252 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:15 UTC sync. A further 2 have not yet opened recruitment, 118 are active but closed to new participants, and 8 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Newcastle upon Tyne), 252 studies
PhaseStudiesRecruitingShare
Phase 31215548%
Phase 2432517.1%
Phase 1/2321712.7%
Observational1997.5%
Phase 11987.5%
Not applicable843.2%
Phase 2/3752.8%
Phase 4311.2%

Most active sponsors

Lead sponsors with the most studies (Newcastle upon Tyne)
Lead sponsorStudiesRecruiting
AstraZeneca1810
Hoffmann-La Roche145
Janssen Research & Development, LLC125
Novartis Pharmaceuticals117
Merck Sharp & Dohme LLC104
Sanofi94
Eli Lilly and Company75
AbbVie63
BioNTech SE65
Boehringer Ingelheim64
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.